D.E. Shaw & Co
FNCH

D.E. Shaw & Co’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

D.E. Shaw & Co’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-639
Closed -$96K – 5955
2022
Q1 		$96K Sell
639
-276
-30% -$63.7K ﹤0.01% 5005
2021
Q4 		$274K Buy
+915
New +$351K ﹤0.01% 4726

Other funds holding FNCH

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AMC
Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
TA
TRB Advisors New York $146M AUM 3.71% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

D.E. Shaw & Co's FNCH Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2022, closing a stake of 639 shares — an estimated $96K sold.

D.E. Shaw & Co first reported a position in FNCH in Q4 2021 and held it in 2 quarters. The position peaked at $274K in Q4 2021. 46 funds tracked by Wall St. Rank hold FNCH as of Q2 2022.

  • D.E. Shaw & Co reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 639 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2022, an estimated $96K.
  • D.E. Shaw & Co first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • D.E. Shaw & Co's Finch Therapeutics Group, Inc. Common Stock position peaked at $274K in Q4 2021.
  • 46 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.